What Di Shuang Treats: Main Uses and Benefits

Di Shuang (Sodium Metamizole) is applied across therapeutic domains where additional symptomatic support is needed for conditions marked by increased discomfort or tension. It is used in the management of acute severe pain and high-intensity fever states.

Core Symptom Domains

The medication is commonly used to help with acute, severe pain, including that associated with injuries or surgical procedures (postoperative pain), as well as tumour-related pain. It is considered relevant for easing symptoms related to heightened physiological activity, specifically the painful cramping of smooth muscles in conditions like renal colic or biliary colic. Furthermore, it is applied in addressing high-grade fever (pyrexia) that can be unresponsive to other standard antipyretics.

Therapeutic Benefits

The supportive relief provided helps ease the overall symptom burden. This combination of pain relief and spasmolytic action may assist with maintaining a sense of stability when symptoms are more noticeable. It supports the management of systemic imbalance by addressing intense pain and fever.

---

Quick Fact: Therapeutic Scope
Di Shuang may assist with managing symptom clusters that include moderate to severe somatic pain, visceral pain, and high fever that create noticeable physiological strain.

Regulatory References

1. European Medicines Agency (EMA) overview

Di Shuang (Sodium Metamizole) eligibility is strictly defined by regulatory authorities and is based on patient susceptibility and physiological state.

Contraindications (Must Not Use)

The medicine is absolutely contraindicated for several populations, including:

• Infants below the age of 3 months or those weighing less than 5 kg.
• Patients with a history of agranulocytosis (blood disorder) induced by metamizole or other similar pyrazolone drugs.
• Individuals with impaired bone marrow function or pre-existing diseases of the haematopoietic system.
• Patients in the third trimester of pregnancy (the final three months).
• Those with known hypersensitivity to the drug or certain metabolic conditions, such as acute hepatic porphyria.

Restricted and Conditional Use

Use is restricted or requires caution in other populations:

• Children and Adolescents (le 14 years) are eligible, but the dose must be determined precisely by body weight.
• Older Adults and patients with impaired renal (kidney) or hepatic (liver) function require dose reduction and caution due to slower elimination of the drug's metabolites.
• Lactation: Repeated use is not recommended; after a single administration, regulatory guidance states that breastmilk must be discarded for 48 hours.

Interactions with other medicines and products

Clinical data on the formal drug-drug interaction profile of Di Shuang with specific Western pharmaceuticals is limited in major governmental regulatory databases, such as those maintained by the FDA or the European Medicines Agency (EMA). Consequently, there are no universally established, officially mandated statements regarding contraindicated drug combinations or dose-adjustment requirements.

Potential Interaction Mechanisms

Information derived from in vitro and network pharmacology studies for certain Traditional Chinese Medicine (TCM) compounds, which may share similar components or mechanisms with Di Shuang, suggests the potential for pharmacokinetic interactions. Some active ingredients found in similar formulas may influence cytochrome P450 (CYP) enzymes, particularly the CYP3A4 metabolic pathway. This enzyme system is crucial for metabolizing a wide range of commonly prescribed medications, including certain statins, immunosuppressants, and anti-infectives. An alteration in CYP enzyme activity could potentially affect the concentration and effect of co-administered drugs.

General Considerations for Combination Use

Due to the complex, multi-component nature typical of such preparations, the possibility of Herb-Drug Interactions (HDIs) should be considered when Di Shuang is taken with any prescription medication. Pharmacodynamic interactions, where the combined effect of two substances is greater than the sum of their individual effects, are also a theoretical possibility. Patients are advised to inform their healthcare providers of all products they are using, including all traditional, herbal, and over-the-counter medicines, to manage potential risks.

How Di Shuang Works: Mechanism of Action

Di Shuang exerts its effect by coordinating action across multiple fundamental regulatory pathways, influencing cell survival, inflammatory response, and tissue homeostasis through a multi-target mechanism.

Regulating Dysregulated Cell Survival Signals

This mechanistic domain covers the drug's role as a modulator of the PI3K/AKT signaling pathway. By inhibiting key enzymes like PIK3CG and AKT1, Di Shuang reduces overactive survival signals, which shifts the cellular balance toward controlled cell death ( apoptosis) via modulation of factors like BCL2 and CASP3. This action facilitates the selective clearance of dysfunctional or damaged cells in affected tissues.

Dampening Pro-Inflammatory Cascades

This domain describes the dual-action inhibition on inflammatory systems. The active components function as inhibitors of PTGS1/COX-1, which reduces the synthesis of local pro-inflammatory mediators ( eicosanoids). Simultaneously, the drug antagonizes the key cytokine TNF, thereby suppressing a major driver of chronic inflammation. The resulting physiological consequence is an attenuation of local inflammation and decreased inflammatory signaling.

Coordinated Multi-Target Modularity

The overall effect results from synergistic multi-target modularity, where multiple ingredients simultaneously engage distinct but interconnected biological targets ( AKT1, TNF, PTGS1). This multi-target mechanism affects both the inflammatory response and cell survival equilibrium, leading to an adjustment of the physiological status.

How to Use Di Shuang

Di Shuang (Sodium Metamizole) administration is characterized by specific parameters regarding the appropriate route, dose, and frequency for its use in acute situations.

---

Administration Routes and Forms

The medication is available in multiple formats to accommodate clinical requirements. These include oral administration (tablets, solution), intravenous (IV) injection or infusion, intramuscular (IM) injection, and rectal administration (suppositories). The form and route are selected based on the required speed of action and feasibility, adhering to established medical principles.

---

Dosing and Frequency Principles

Administration follows the principle of using the lowest effective dose for the shortest possible duration.

Usage Parameter	Clinical Parameters
Standard Single Dose	Up to 1,000 mg orally for adults (ge 15 years and > 53 kg).
Maximum Daily Dose	4,000 mg for oral administration.
Dosing Interval	A minimum of 6 to 8 hours must pass between doses.

For the pediatric population (under 15 years), use is strictly weight-dependent, with a single dose typically calculated in the range of 8 to 16 mg per kg of body weight. Furthermore, dose reduction is typically indicated for older adults and individuals with reduced renal or hepatic function.

---

Procedural Constraints

When administering the solution for injection, a key procedural step is that the intravenous injection must be performed slowly. This ensures correct administration and is a requirement for the safe delivery of the parenteral form.

Research evidence / Overview of studies for Di Shuang (Sodium Metamizole)

Evidence for Acute Pain Relief and Spasmolytic Use

Research exploring acute pain relies on numerous short-term Randomized Controlled Trials (RCTs) and Meta-analyses conducted in adult populations, such as those with postoperative pain. Studies primarily monitored changes in pain intensity over the initial 4 to 6 hours following a single dose. For visceral pain (colic), trials also explored outcomes related to the need for further analgesic treatment. The quality of trial reporting is often described as mediocre, and the evidence is heavily focused on very short-term results.

Evidence for High Fever Reduction (Antipyretic Use)

Fever research also includes RCTs and Meta-analyses that have examined changes in body temperature. The research involved both adults and febrile children, monitoring temperature outcomes at frequent intervals within the initial eight hours. Findings were mixed when studies were evaluated alongside other standard compounds, and research on direct comparisons in broader adult populations remains limited compared to pediatric data.

Evidence for Chronic Pain Management

Research explored Di Shuang in studies examining tumor-related pain (neoplastic pain). The evidence is derived from a small number of RCTs and data summarized in Systematic Reviews. Studies monitored outcomes related to physical discomfort and reported patterns in the change in opioid medication dosages over periods of days or weeks. However, comparative evidence is lacking against other non-opioid options for this specific chronic pain type.

Key Research Gaps and Uncertainty

The overall evidence base is characterized by significant limitations. Long-term effects are not fully established, as trials were generally not designed to monitor sustained outcomes over months or years. The certainty remains low regarding long-term outcomes, and there is limited information beyond the short-term resolution of acute symptoms. Data for certain groups, such as older adults with multiple conditions, remain insufficient, and the results apply only to the populations studied.

Common questions about Di Shuang (FAQ)

Q: Can I use Di Shuang if I am breastfeeding?

According to official regulatory guidance, repeated use of this medicine is not recommended while breastfeeding. If a single dose is administered, regulatory guidance recommends discarding breastmilk for a period of 48 hours following the dose.

---

Q: What conditions make me ineligible to take this medicine?

Official product information defines several conditions where use is contraindicated. These include infants under a certain age or weight, patients with a history of blood disorders (like agranulocytosis) induced by metamizole, existing impaired bone marrow function, and use during the third trimester of pregnancy. Other contraindications relate to certain metabolic conditions.

---

Q: What other medications should I avoid taking with Di Shuang?

Official drug labeling indicates that Di Shuang may interact with certain other medicines, potentially requiring caution or avoidance. For example, it is known to reduce the effect of the immunosuppressant drug cyclosporine and can reduce the concentration of bupropion. The official product label also advises caution, noting that the combination with methotrexate may increase the risk of blood toxicity.

---

Q: How quickly does Di Shuang start working?

Studies and official product information indicate that the analgesic (pain-relieving) effect of the medicine begins relatively quickly. Following oral administration, a clear effect is generally expected within 30 to 60 minutes. After an injection (parenteral administration), the effect typically begins within 30 minutes.

---

Q: What should I do in case of an overdose?

Official guidance indicates that if an overdose is suspected, immediate medical attention is necessary. Regulatory documents identify key symptoms of acute overdose, which may include digestive symptoms like nausea, vomiting, or stomach pain. Overdose can also affect the kidneys, lead to reduced blood pressure (hypotension), and cause central nervous system effects like drowsiness or confusion.

---

Q: What should I do if I get an allergic reaction to Di Shuang?

Regulatory documents recommend that patients stop taking the medicine and seek immediate medical attention if signs of a serious allergic reaction or a blood disorder (like agranulocytosis) are noticed. These signs can include fever, chills, a severe sore throat, or painful sores on moist body surfaces.

Official Storage and Disposal Instructions

Official regulatory documents define strict conditions for the safe storage and disposal of Di Shuang (Sodium Metamizole) products to maintain stability and protect the environment.

Storage Conditions

• Temperature: The product must be stored below 25 C and not refrigerated or frozen.
• Protection: The medicine must be kept in a dry place, away from light, with the container kept tightly closed.
• Safety: The product must be stored locked up and kept out of the reach of children.
• Stability: Specific liquid formulations have a limited in-use period, often requiring disposal if unused after 28 days following the first opening.

Disposal Requirements

Disposal must be handled according to local requirements, strictly prohibiting release to the environment. Unused or expired contents must not enter sewers, surface water, or groundwater and must be disposed of via an approved waste disposal plant.